| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(16)00175-3 |
| P698 | PubMed publication ID | 27157491 |
| P50 | author | Hyun Cheol Chung | Q59647646 |
| Yung-Jue Bang | Q16180903 | ||
| P2093 | author name string | Dung T Le | |
| Minori Koshiji | |||
| Talia Golan | |||
| Chia-Chi Lin | |||
| Shilpa Gupta | |||
| Kei Muro | |||
| Autumn J McRee | |||
| Barbara Burtness | |||
| Veena Shankaran | |||
| Kenneth Emancipator | |||
| Ravit Geva | |||
| Jonathan Juco | |||
| Jared Lunceford | |||
| Joseph Paul Eder | |||
| Daniel Catenacci | |||
| Kumudu Pathiraja | |||
| P2860 | cites work | Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue | Q38377655 |
| PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies | Q40185070 | ||
| Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection | Q40313152 | ||
| Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. | Q41228724 | ||
| Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma | Q43788672 | ||
| Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. | Q53249720 | ||
| Gastric cancer | Q57758203 | ||
| Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance | Q82793374 | ||
| Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer | Q87494688 | ||
| Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance | Q87827796 | ||
| Gastric cancer: prevention, screening and early diagnosis | Q26860418 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Medical management of gastric cancer: a 2014 update | Q34326546 | ||
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | Q34670965 | ||
| Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer | Q35113261 | ||
| Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer | Q35554809 | ||
| Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity | Q35870655 | ||
| P433 | issue | 6 | |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| pembrolizumab | Q13896859 | ||
| P304 | page(s) | 717-726 | |
| P577 | publication date | 2016-05-03 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | |
| P478 | volume | 17 |
| Q49645479 | A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer |
| Q47569586 | A case of gastric cancer metastasis to the breast in a female with BRCA2 germline mutation and literature review. |
| Q38738402 | A global burden of gastric cancer: the major impact of China. |
| Q55227468 | A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. |
| Q50074651 | A selective sphingosine-1-phosphate receptor 1 agonist SEW-2871 aggravates gastric cancer by recruiting myeloid-derived suppressor cells |
| Q33577624 | A unified model of the hierarchical and stochastic theories of gastric cancer |
| Q48517891 | Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma |
| Q92594147 | Adenosine Generated by Regulatory T Cells Induces CD8+ T Cell Exhaustion in Gastric Cancer through A2aR Pathway |
| Q39091817 | Advanced gastric adenocarcinoma: optimizing therapy options. |
| Q90318996 | Advancements and challenges in treating advanced gastric cancer in the West |
| Q55506755 | Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. |
| Q104459144 | An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer |
| Q38956298 | An update in the nonendoscopic treatment of gastric cancer |
| Q59350023 | Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) |
| Q55256764 | Approach and management of checkpoint inhibitor-related immune hepatitis. |
| Q55279175 | Association between angiogenesis and cytotoxic signatures in the tumor microenvironment of gastric cancer. |
| Q40277904 | Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy |
| Q61800297 | Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial |
| Q33895597 | Biologic therapy in esophageal and gastric malignancies: current therapies and future directions |
| Q98166049 | CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors |
| Q47142001 | CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease |
| Q52565789 | CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer. |
| Q38679662 | Cancer Immunotherapies: Are They as Effective in the Elderly? |
| Q92922157 | Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments |
| Q37737940 | Cancer immunotherapies targeting the PD-1 signaling pathway |
| Q94526290 | Cautious optimism-the current role of immunotherapy in gastrointestinal cancers |
| Q50231313 | Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies |
| Q39038994 | Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety |
| Q58775775 | CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer |
| Q58576243 | Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy? |
| Q56891504 | Checkpoint blockade in esophagogastric cancer |
| Q90321355 | Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies |
| Q42353443 | Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality |
| Q54966594 | Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis. |
| Q38604012 | Chemotherapy for advanced gastric cancer. |
| Q38815071 | Chemotherapy for advanced gastric cancer: future perspective in Japan |
| Q60958618 | Clinical Significance of CUB and Sushi Multiple Domains 1 Inactivation in Head and Neck Squamous Cell Carcinoma |
| Q64115689 | Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers |
| Q64452765 | Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse |
| Q90321333 | Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond |
| Q59789596 | Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies |
| Q55096369 | Clinical significance of circulating tumor cells in blood from patients with gastric cancer. |
| Q41169821 | Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology |
| Q64983989 | Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. |
| Q33688662 | Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients |
| Q92646254 | Clinicopathological features and prognostic value of mismatch repair protein deficiency in gastric cancer |
| Q28066199 | Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy |
| Q49700084 | Combination of anti-PD-1 therapy and stereotactic radiosurgery for a gastric cancer patient with brain metastasis: a case report |
| Q41708934 | Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers |
| Q52603962 | Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. |
| Q102388956 | Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer |
| Q59356808 | Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer |
| Q90148001 | Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting |
| Q28076294 | Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment |
| Q96132801 | Current Molecular Targeted Agents for Advanced Gastric Cancer |
| Q39389346 | Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers |
| Q58594584 | Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies |
| Q55036846 | Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). |
| Q55715408 | Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. |
| Q52643527 | Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. |
| Q52581752 | Current therapeutic landscape for advanced gastroesophageal cancers. |
| Q55033047 | Customization of therapy for gastroesophageal adenocarcinoma patients. |
| Q90433471 | Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group |
| Q58609277 | Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic |
| Q42371631 | Development of mesenchymal subtype gene signature for clinical application in gastric cancer |
| Q37626654 | Distal gastrectomy versus total gastrectomy for distal gastric cancer |
| Q99637183 | Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients |
| Q91895820 | Downregulated Expression of hsa_circ_0005556 in Gastric Cancer and Its Clinical Significance |
| Q39069273 | Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. |
| Q90353958 | Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States |
| Q92433650 | Effect of anti-PD-1 antibody, nivolumab on early gastric cancer |
| Q89529851 | Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response |
| Q91868485 | Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis |
| Q89326677 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 |
| Q98164819 | Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials |
| Q57111080 | Emerging Therapies in the Management of Advanced-Stage Gastric Cancer |
| Q33617949 | Emerging therapies for breast cancer |
| Q61867568 | Encouraging results for PD-1 inhibition in gastric cancer |
| Q90427403 | Enumeration And Characterization Of Circulating Tumor Cells And Its Application In Advanced Gastric Cancer |
| Q64288065 | Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer |
| Q89927058 | Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma |
| Q52802735 | Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. |
| Q90452117 | Esophageal, gastric cancer and immunotherapy: small steps in the right direction? |
| Q64893921 | Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma. |
| Q47387155 | Expression of programmed death-1 in sentinel lymph nodes of breast cancer. |
| Q98289752 | FOXP3+ Tregs exhibit different infiltrating status and predict a distinct prognosis in primary lesions and hepatic metastases in stage III&IV advanced gastric cancer |
| Q57792110 | FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma |
| Q38695286 | Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer. |
| Q64103596 | Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times |
| Q54238201 | Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. |
| Q45952214 | From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. |
| Q90446444 | Gastric Cancer in Young Adults: A Different Clinical Entity from Carcinogenesis to Prognosis |
| Q33600457 | Gastric Cancer in the Era of Precision Medicine |
| Q88463123 | Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States |
| Q90468018 | Gastric adenocarcinoma is concurrent with metastatic neuroendocrine cancer treated with nivolumab and chemotherapy: A case report |
| Q39343374 | Gastric adenocarcinoma. |
| Q38749038 | Gastric cancer management: Kinases as a target therapy |
| Q55057845 | Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil. |
| Q50168318 | Gastric cancer: Basic aspects. |
| Q28073757 | Gastric cancer: current and evolving treatment landscape |
| Q90698029 | Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors |
| Q47584566 | Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. |
| Q41173680 | Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. |
| Q42380545 | Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. |
| Q38779428 | Genomic pathobiology of gastric carcinoma |
| Q38813532 | Global chemotherapy development for gastric cancer |
| Q96134534 | Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections |
| Q94595001 | High-dimensional analyses reveal a distinct role of T-cell subsets in the immune microenvironment of gastric cancer |
| Q91964579 | Hyperprogression after immunotherapy in patients with malignant tumors of digestive system |
| Q96305347 | IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer |
| Q64116162 | Identification of genomic features associated with immunotherapy response in gastrointestinal cancers |
| Q47443241 | Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. |
| Q39328076 | Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management |
| Q39387816 | Immune Checkpoints as a Target for Colorectal Cancer Treatment. |
| Q58737377 | Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers |
| Q97643978 | Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives |
| Q64249000 | Immune checkpoint inhibitors in esophagogastric cancer: still a long way to go |
| Q55255694 | Immune checkpoint inhibitors in gastrointestinal malignancies. |
| Q47400647 | Immune checkpoint inhibitors: new strategies to checkmate cancer |
| Q90950852 | Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression |
| Q47101155 | Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis |
| Q87594576 | Immune-checkpoint inhibition for digestive cancers |
| Q52649601 | Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients. |
| Q54970085 | Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. |
| Q57068038 | Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial |
| Q92616105 | Immunological Agents Used in Cancer Treatment |
| Q55652343 | Immunotherapy for Gastric Cancer: Time for a Personalized Approach? |
| Q28069873 | Immunotherapy for Gastroesophageal Cancer |
| Q38738652 | Immunotherapy for gastric cancers: emerging role and future perspectives |
| Q90354330 | Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies |
| Q91942638 | Immunotherapy in Esophagogastric Adenocarcinoma |
| Q53183990 | Immunotherapy in Gastrointestinal Cancers. |
| Q39453597 | Immunotherapy in gastrointestinal cancers |
| Q91424525 | Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis |
| Q64946696 | Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors. |
| Q47117702 | Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection? |
| Q47705923 | Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. |
| Q47211203 | Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience |
| Q55002224 | Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. |
| Q33775283 | Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma |
| Q48293633 | Inhibitors of the PD-1 Pathway in Tumor Therapy |
| Q33711746 | Initiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells |
| Q92354829 | Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer |
| Q100992474 | Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells |
| Q92841176 | Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines |
| Q64076485 | Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach |
| Q61807014 | LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers |
| Q88013125 | Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers |
| Q60044246 | Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer |
| Q57787094 | MGCD0103 induces apoptosis and simultaneously increases the expression of NF-κB and PD-L1 in classical Hodgkin's lymphoma |
| Q93063710 | Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry |
| Q55314300 | Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. |
| Q47312688 | Medical management of gastric cancer: a 2017 update |
| Q64254680 | Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer |
| Q90479399 | MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers |
| Q90019254 | Microbial biomarkers for immune checkpoint blockade therapy against cancer |
| Q56889396 | Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches |
| Q55025461 | Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets. |
| Q92035014 | Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features |
| Q33696201 | Molecular classifications of gastric cancers: Novel insights and possible future applications |
| Q57490881 | Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the |
| Q96950785 | Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer |
| Q92137757 | Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors |
| Q40204803 | Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. |
| Q38759129 | New agents on the horizon in gastric cancer |
| Q59136693 | New drug developments in metastatic gastric cancer |
| Q59182198 | New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression |
| Q54261019 | Next generation sequencing-based emerging trends in molecular biology of gastric cancer. |
| Q47745009 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q46360036 | Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review |
| Q92824998 | Novel Biomarkers for Personalized Cancer Immunotherapy |
| Q98466119 | Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction? |
| Q52645038 | Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. |
| Q52599496 | Novel Systemic Therapies for Advanced Gastric Cancer. |
| Q39171565 | Novel Targeted Therapies for Esophagogastric Cancer |
| Q47936526 | Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies |
| Q55280819 | Optimal Collaborative Management of Patients With Esophagogastric Cancers. |
| Q40416586 | Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications |
| Q92535630 | PD-1 Inhibitors in the Advanced Esophageal Cancer |
| Q38649562 | PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence |
| Q38642853 | PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. |
| Q91828801 | PD-L1 Expression Is Regulated By NF-κB During EMT Signaling In Gastric Carcinoma |
| Q55554951 | PD-L1 Expression and CD8+ T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer. |
| Q64983568 | PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. |
| Q59329686 | PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N) |
| Q55394623 | PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers. |
| Q48184221 | PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. |
| Q49968394 | PD-L1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer |
| Q64114324 | POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma |
| Q55606632 | Paraneoplastic NMOSD associated with EG junction adenocarcinoma expressing unprotected AQP4. |
| Q92619104 | Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study |
| Q39193035 | Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. |
| Q49925686 | Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study |
| Q57483927 | Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy |
| Q47864236 | Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma |
| Q55253213 | Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. |
| Q64968885 | Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer. |
| Q90264677 | Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial |
| Q47139613 | Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer |
| Q94465339 | Precision Medicine in Non Communicable Diseases |
| Q96155607 | Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers |
| Q39170872 | Predictive biomarkers along gastric cancer pathogenetic pathways |
| Q47137632 | Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer |
| Q89450684 | Preface: More than two decades of modern tumor immunology |
| Q91284516 | Preface: More than two decades of modern tumor immunology |
| Q95591987 | Preface: More than two decades of modern tumor immunology |
| Q99630432 | Primary Gastric Adenosquamous Carcinoma: A Case Report |
| Q55086934 | Prognostic Value of Immunoscore and PD-L1 Expression in Metastatic Colorectal Cancer Patients with Different RAS Status after Palliative Operation. |
| Q49309172 | Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis. |
| Q57167306 | Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer |
| Q41967898 | Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma |
| Q39013253 | Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma |
| Q55311366 | Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. |
| Q37706604 | Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability |
| Q93107202 | Programmed death ligand 1 (PD-L1) expression in parathyroid tumors |
| Q47143363 | Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection |
| Q98159772 | Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges |
| Q55307728 | Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. |
| Q90215912 | Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China |
| Q91851580 | Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial |
| Q92591000 | Regulatory T cells and M2 macrophages present diverse prognostic value in gastric cancer patients with different clinicopathologic characteristics and chemotherapy strategies |
| Q92697400 | Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer |
| Q92058622 | Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer |
| Q101139011 | Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma |
| Q33593871 | Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress |
| Q53837214 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. |
| Q39084242 | Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study |
| Q33608156 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. |
| Q91821601 | Safety and efficacy of toripalimab in advanced gastric cancer: A new clinical trial bringing hope for immunotherapy in gastric cancer |
| Q47164715 | Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events |
| Q88654117 | Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study |
| Q93005169 | Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 |
| Q38750633 | Second-line chemotherapy for patients with advanced gastric cancer. |
| Q55223567 | Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. |
| Q91691739 | Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy |
| Q64234259 | Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma |
| Q92382425 | Significant function and research progress of biomarkers in gastric cancer |
| Q55196621 | Single agent anti PD-1 inhibitors in esophageal cancer-a first step in a new therapeutic direction. |
| Q91612580 | Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type |
| Q97529931 | Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma |
| Q90333943 | Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers |
| Q41340207 | Targeted therapies for gastric cancer: failures and hopes from clinical trials |
| Q49961144 | Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma |
| Q92408693 | Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies |
| Q102210856 | Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies |
| Q33888982 | The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy |
| Q98292001 | The Role of Gastric Mucosal Immunity in Gastric Diseases |
| Q56890968 | The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors |
| Q58561576 | The clinical role of the TME in solid cancer |
| Q55383833 | The direction of travel to better outcomes for patients with oesophago-gastric cancer. |
| Q90402575 | The evolving immunotherapeutic landscape in advanced oesophagogastric cancer |
| Q39183864 | The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring |
| Q90087481 | The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma |
| Q50921394 | The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. |
| Q61812340 | Therapeutic Potential of Natural Killer Cells in Gastric Cancer |
| Q57211498 | Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes |
| Q90300273 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis |
| Q47728785 | Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. |
| Q42376660 | Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry |
| Q52654643 | Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. |
| Q91584498 | Use of immunotherapy in the treatment of gastric cancer |
| Q57159608 | What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives |
| Q52689973 | When worlds collide: Th17 and Treg cells in cancer and autoimmunity. |
| Q53496282 | [Current biomarkers for gastric cancer]. |
| Q53750080 | [Novel pharmaceutical treatment approaches for gastric cancer]. |
Search more.